On Monday, Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of ... Price Action: INCY stock is down 11.90% at $59.78 at the last ...
Incyte's Phase 3 STOP-HS trials showed povorcitinib met primary ... Price Action: INCY stock is down 11.90% at $59.78 at the last check Monday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback